111 related articles for article (PubMed ID: 6763881)
1. Immune reactivity of spleen cells in advanced stages of tumor growth.
Oisgold-Dagá S; Jasnis MA; Klein S; de Bonaparte YP
Biomed Pharmacother; 1982; 36(6-7):319-23. PubMed ID: 6763881
[TBL] [Abstract][Full Text] [Related]
2. Tumor delayed hypersensitivity reactions. "In vivo" functional differences between spleen and peripheral blood lymphocytes.
de Bonaparte YP; Oisgold-Dagá S; Klein S; Stillitani-D'Elia I
Biomedicine; 1980 Feb; 33(1):16-8. PubMed ID: 7370382
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of mouse migration inhibitory factor (MIF) production form MSV-immune lymphocytes by soluble tumor-associated antigen: requirement for histocompatible macrophages.
Landolfo S; Herberman RB; Holden HT
J Immunol; 1977 Apr; 118(4):1244-8. PubMed ID: 191532
[TBL] [Abstract][Full Text] [Related]
4. Immune RNA-mediated transfer of tumor antigen responsiveness to unresponsive peritoneal exudate cells from tumor-bearing animals.
Braun DP; Dray S
Cancer Res; 1977 Nov; 37(11):4138-44. PubMed ID: 908048
[TBL] [Abstract][Full Text] [Related]
5. Cellular immunity to solubilized tumor antigens of a methylcholanthrene-induced sarcoma with a migration inhibition assay.
Padarathsingh ML; Dean JH; McCoy JL; Lewis DD; Northing JW; Natori T; Law LW
J Immunol; 1978 Jun; 120(6):1981-5. PubMed ID: 659888
[TBL] [Abstract][Full Text] [Related]
6. [Effect of the splenic cells of tumor-bearing mice on the allograft immune response].
Spasokukotskiĭ AL
Vopr Onkol; 1985; 31(7):87-91. PubMed ID: 4024565
[TBL] [Abstract][Full Text] [Related]
7. Indirect leukocyte migration inhibition in breast cancer and benign breast disease patients by mouse mammary tumor virus grown in feline kidney cells.
McCoy JL; Tagliabue A; Ames RE; Teramoto YA; Cannon GB; Alford C; Herberman RB; Schlom J
J Natl Cancer Inst; 1984 Mar; 72(3):569-76. PubMed ID: 6321840
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the macrophage electrophoretic mobility test and the leukocyte migration inhibition test in the detection of histocompatibility antigens on tumor cells.
Bubeník J; Cochran AJ; Todd G; Malkovský M; Jandlová T; Suhajová E; Boubelík M
Neoplasma; 1981; 28(2):185-93. PubMed ID: 7019742
[TBL] [Abstract][Full Text] [Related]
9. [Participation of spleen cells in regulating the production of macrophage migration inhibitory factor in mice].
Koval'chuk LV; Sotnikova NIu
Biull Eksp Biol Med; 1981 Mar; 91(3):336-8. PubMed ID: 7018617
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
[TBL] [Abstract][Full Text] [Related]
11. Apparent lack of immunogenicity of estrogen-induced testicular Leydig cell tumors in BALB/c mice.
Huseby RA; Page RH
Cancer Res; 1982 Nov; 42(11):4332-8. PubMed ID: 6751521
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
13. Cellular cytotoxicity and serum inhibition in normal mice following transfer of syngeneic tumor-sensitized cells.
Fisher B; Wolmark N; Saffer EA
J Natl Cancer Inst; 1980 Mar; 64(3):579-85. PubMed ID: 6986497
[TBL] [Abstract][Full Text] [Related]
14. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
15. [Kinetics of production of macrophage migration inhibitory factors in mixed culture of lymphocytes and tumor cells].
Kharkevich DD; Suslov AP
Biull Eksp Biol Med; 1982 Feb; 93(2):53-5. PubMed ID: 6461371
[No Abstract] [Full Text] [Related]
16. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
[TBL] [Abstract][Full Text] [Related]
17. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
18. Evidence of dual function of macrophage migration inhibitory factor relevant to tumor progression and regression.
Fukushima T; Nishihira J; Yoshiki T; Iwabuchi K; Iwabuchi C; Yamasaki Y; Kondo M; Sun B; Sato Y; Todo S
Int J Mol Med; 2005 Jul; 16(1):119-26. PubMed ID: 15942688
[TBL] [Abstract][Full Text] [Related]
19. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific activity of murine leukocyte dialysates containing transfer factor on human leukocytes in the leukocyte migration inhibition (LMI) assay.
Borkowsky W; Suleski P; Bhardwaj N; Lawrence HS
J Immunol; 1981 Jan; 126(1):80-2. PubMed ID: 6161170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
